Alcoholic liver disease (ALD) is understood in Ayurveda under the broader clinical umbrella of Yakrit Vikara and Kamala, arising from Pittadushti and Kaphavriddhi with progressive Yakrit-Pliha Vriddhi and, in advanced stages, Jalodara (ascites) resembling decompensated cirrhosis. The formulation examined in this review is a tetra-herbal combination of Haridra (Curcuma longa Linn.), Bhumi-Amalaki (Phyllanthus urinaria Linn.), Pippali (Piper longum Linn.) and Jiraka (Cuminum cyminum Linn.), combined in equal (1:1:1:1) proportion.

Each of these dravyas is independently described in classical Ayurvedic literature as possessing Yakrit-uttejaka (hepatostimulant), Deepana-Pachana (digestive-carminative) and Kaphapittahara properties^1,2,3,4, and each has, over the last two decades, accumulated a substantial body of experimental and clinical pharmacological evidence supporting a hepatoprotective role, including specifically in ethanol-induced hepatic injury. This review consolidates the classical Ayurvedic description of each ingredient with contemporary research evidence, so as to build the scientific rationale for their combined use in the management of alcoholic liver disease.

2. Individual Drug Review

2.1 Haridra (Curcuma longa Linn.)

Classically, Haridra is regarded as a premier Yakrit-uttejaka (hepatic stimulant) dravya, and is credited with anti-inflammatory, antioxidant, anti-allergic, rejuvenative, antimicrobial, detoxifying and anti-cancer properties^1,2,3,4. Its rhizome yields 5–8% volatile oil along with the diarylheptanoid curcumin, besides fat, protein, albumin, carbohydrate, vitamin A and minerals^3,4.

Contemporary Research Update

Curcumin, the principal bioactive curcuminoid of Haridra, has been used as a hepatoprotective agent in Ayurveda and traditional Chinese medicine for centuries, and a growing body of mechanistic work has now examined its action specifically in alcoholic liver injury^5,6. In a chronic-alcohol mouse model, curcumin supplementation attenuated ethanol-induced hepatic damage by correcting mitochondrial antioxidant enzyme activity and membrane potential, and by suppressing endoplasmic-reticulum-stress and NF-κB-driven inflammatory signalling, indicating a dual mitochondrial-protective and anti-inflammatory mechanism of action⁸.

A systematic mechanistic review covering three decades of literature similarly concluded that curcumin consistently reduces ethanol-induced oxidative stress, lipid peroxidation, inflammatory cytokine release and hepatocyte apoptosis across multiple animal models⁹, and a hot-water turmeric extract has been shown to suppress acute ethanol-induced liver injury in mice through inhibition of hepatic oxidative stress and inflammatory cytokine production¹⁰.

In the clinical setting, a double-blind randomised placebo-controlled trial of a curcumin-galactomannoside complex in chronic alcoholic patients demonstrated measurable improvement in hepatic function markers, supporting translational relevance of the pre-clinical findings to human alcoholic liver disease¹¹. Curcumin has also shown benefit on hepatic fibrosis and inflammatory markers in trials on fatty liver disease¹², and a recent narrative review highlights its modulation of the NF-κB, TGF-β/Smad and Nrf2 pathways as the shared mechanistic basis for its efficacy across steatotic, inflammatory and fibrotic liver conditions, while noting that nanoformulation strategies are being explored to overcome its inherently low oral bioavailability¹³.

2.2 Bhumi-Amalaki (Phyllanthus urinaria Linn.)

Bhumi-Amalaki is classically indicated as the drug of choice for Kamala (jaundice) and for Yakrit-Pliha Vriddhi with Jalodara (ascites), corresponding closely to hepatosplenomegaly with fluid accumulation seen in decompensated liver disease^1,2,3,4. Its principal constituents include the tannins corilagin and geraniin, the flavonoids quercetin and rutin, phenolic acids such as gallic and ellagic acid, the lignan phyllanthin, and assorted terpenoids, which together underlie its reported antioxidant, hepatoprotective, antiviral and anti-inflammatory actions^3,4,7.

Contemporary Research Update

A comprehensive 2024 review of Phyllanthus urinaria in liver disease documents its established capacity to lower elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in animal models of hepatic injury, and summarises evidence of efficacy across viral hepatitis, liver fibrosis/cirrhosis and hepatocellular carcinoma, attributing these effects to its rich content of lignans, flavonoids and tannins acting through antioxidant and anti-inflammatory pathways¹⁴. Related Phyllanthus species within the same genus have additionally shown hepatoprotective benefit in non-alcoholic fatty liver disease models, and constituent phenolics such as quercetin and ellagic acid — both present in Bhumi-Amalaki — have independently been shown to reduce oxidative and fibrotic liver injury by modulating hepatic macrophage polarisation and toll-like-receptor/NF-κB signalling, providing plausible constituent-level mechanistic support for its classical use in Kamala and Yakrit-Pliha Vriddhi⁷.

2.3 Pippali (Piper longum Linn.)

Pippali is classically valued as a Yakrit-Plihodara-hara dravya and as a Yoga-vahi (bio-enhancer) that potentiates the action of co-administered drugs^1,2,3,4. Charaka Samhita specifically describes Pippali Rasayana and Vardhamana Pippali Kalpana among the best formulations for Yakrit (liver) disorders²³. Its fruit contains 0.7% pungent volatile oil, 4–5% piperine alkaloid, along with piplartine, sesamin and the steroid piperlongumine (piplasterol)^3,4.

Contemporary Research Update

Piperine, the chief alkaloid of Pippali, has demonstrated significant hepatoprotective activity against tert-butyl hydroperoxide- and carbon tetrachloride-induced hepatotoxicity, and a milk-processed extract of Piper longum produced hepatoprotection comparable to silymarin in normalising serum transaminases and bilirubin¹⁵. Piperine has separately been shown to attenuate acetaminophen-induced hepatotoxicity through membrane-stabilising and antioxidant activity¹⁷, and to reduce thioacetamide-induced hepatic fibrosis in mice via modulation of the miR-17 and TGF-β/Smad signalling axis, indicating an anti-fibrotic action relevant to progressive alcoholic liver disease¹⁸.

Of particular relevance to this formulation, a network-pharmacology and in-vivo study on Trikatu Churna — a classical formulation containing Piper longum together with Piper nigrum and Zingiber officinale — demonstrated dose-dependent hepatoprotective effects specifically against ethanol-induced alcoholic liver disease in an animal model, lending direct pre-clinical support to the inclusion of Pippali in a formulation intended for ALD¹⁶.

2.4 Jiraka (Cuminum cyminum Linn.)

Jiraka is classically indicated for Agnimandya (indigestion), Adhmana (flatulence), abdominal pain and Daha (burning sensation), functioning primarily as a Deepana-Pachana (digestive-carminative) dravya^1,2,3,4. Its seeds yield 2–4% volatile oil rich in cuminaldehyde, together with protein, carbohydrate, calcium, phosphorus, vitamin C and iron^3,4.

Contemporary Research Update

Experimental work has shown that Cuminum cyminum supplementation reduces hepatic lipid accumulation and normalises elevated AST, alkaline phosphatase and gamma-glutamyl transferase levels induced by combined alcohol and thermally-oxidised-oil feeding in rats, indicating a protective action against alcohol-associated hepatotoxicity and lipid peroxidation¹⁹. A related study confirmed that cumin restores glutathione, vitamin C, vitamin E and antioxidant enzyme (superoxide dismutase, catalase, glutathione peroxidase) activity that is otherwise depleted by ethanol and oxidised-oil exposure²⁰. Cumin seed powder has further been shown to prevent oxidative stress, hyperlipidaemia and fatty liver changes in high-fat-diet-fed rats²², and a comparative hepatoprotective study found Cuminum cyminum extract to be at least as effective as Phyllanthus emblica in normalising liver enzymes in a hepatotoxicity model, supporting its rationale as the Deepana-Pachana and antioxidant component of the formulation²¹.

3. Synthesis: Combined Rationale for Use in Alcoholic Liver Disease

Taken together, the four ingredient dravyas act on complementary aspects of the pathophysiology of alcoholic liver disease. Haridra and Bhumi-Amalaki contribute antioxidant, anti-inflammatory and hepatocyte-protective actions relevant to ethanol-induced oxidative stress, NF-κB-mediated inflammation and evolving fibrosis^{7,8,9,10,11,12,13,14}; Pippali, besides direct hepatoprotective and anti-fibrotic activity, functions as a Yoga-vahi that may enhance the bioavailability of the co-administered ingredients^{15,16,17,18,23}; and Jiraka provides Deepana-Pachana support and additional antioxidant action against alcohol- and lipid-peroxidation-induced hepatic injury^19,20,21,22.

This convergence between the classical Ayurvedic description of each dravya as Yakrit-uttejaka, Kaphapittahara and Deepana-Pachana, and the modern pharmacological evidence of anti-oxidative, anti-inflammatory and anti-fibrotic activity in ethanol-induced hepatic injury models, provides the scientific and classical basis for evaluating this tetra-herbal combination in the management of alcoholic liver disease.

Conclusion

The tetra-herbal combination of Haridra, Bhumi-Amalaki, Pippali and Jiraka brings together classically validated hepatoprotective, digestive-carminative and Kaphapittahara actions with a converging body of modern pharmacological evidence demonstrating anti-oxidative, anti-inflammatory and anti-fibrotic effects specifically relevant to ethanol-induced liver injury. The complementary mechanisms of each ingredient — spanning mitochondrial protection, NF-κB and TGF-β/Smad pathway modulation, antioxidant enzyme restoration and bioavailability enhancement — together support the rational basis for this formulation's use in the clinical management of alcoholic liver disease (Madyaja Yakrit Vikara), and justify its further evaluation in controlled clinical trials.

REFERENCES

1. The Ayurvedic Pharmacopoeia of India, Part-I, 1st ed. New Delhi: Government of India, Ministry of Health and Family Welfare, 1990; p.45. ISBN 81-901151-3-8.
2. Bapalal G Vaidya. Nigantu Adarsha, Uttardha. Varanasi: Chaukhambha Bharati Academy; 2020. p.559. ISBN 978-81-909872-0-2.
3. Sastry JLN (forwarded by Chunekar KC). Illustrated Dravyaguna Vijnana, Vol 2. Reprint ed. Varanasi: Chaukhambha Orientalia; 2010. p.112–514, 272–274, 452–455, 930–932.
4. Sharma PV. Dravyaguna Vijnana, Vol 2. Reprint ed. Varanasi: Chaukhambha Bharati Academy; 2012. p.275–276.
5. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.
6. Gupta AK, Misra N. The therapeutic role of Curcuma longa: a review. J Ayurveda Integr Med. 2012;3(2):93–98.
7. Fang SH, Rao YK, Tzeng YM. Anti-oxidant and inflammatory mediator's growth inhibitory effects of compounds isolated from Phyllanthus urinaria. J Ethnopharmacol. 2008;116(2):333–340.
8. Yang X, et al. Protective effects of curcumin against chronic alcohol-induced liver injury in mice through modulating mitochondrial dysfunction and inhibiting endoplasmic reticulum stress. PMC6852329, Front Pharmacol. 2019.
9. Farzaei MH, et al. Curcumin can act as an effective agent for prevention or treatment of alcohol-induced toxicity in hepatocytes: an illustrated mechanistic review. Iran J Pharm Res. 2021.
10. Uchio R, Higashi Y, Kohama Y, Kawasaki K, Hirao T, Muroyama K, Murosaki S. A hot water extract of turmeric (Curcuma longa) suppresses acute ethanol-induced liver injury in mice by inhibiting hepatic oxidative stress and inflammatory cytokine production. J Nutr Sci. 2017;6:e3.
11. Kulkarni R, et al. A novel curcumin-galactomannoside complex delivery system improves hepatic function markers in chronic alcoholics: a double-blinded, randomized, placebo-controlled study. PMC6174784. Nutrients/J Clin Trials. 2018.
12. Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo-controlled clinical trial. BMC Gastroenterol. 2019;19:133.
13. Xu XA, et al. Curcumin: a natural warrior against inflammatory liver diseases. Nutrients. 2025;17(8):1373.
14. Liu L, Wang B, Ma Y, Sun K, Wang P, Li M, Dong J, Qin M, Li M, Wei C, Tan Y, He J, Guo K, Yu XA. A review of Phyllanthus urinaria L. in the treatment of liver disease: viral hepatitis, liver fibrosis/cirrhosis and hepatocellular carcinoma. Front Pharmacol. 2024;15:1443667.
15. Manjunatha BK, et al. Hepatoprotective activity of Piper longum traditional milk extract on carbon tetrachloride induced liver toxicity in Wistar rats. Indian J Pharmacol / Res Gate archive, 2009.
16. Kumar S, et al. Deciphering the impact and mechanism of Trikatu, a spices-based formulation, on alcoholic liver disease employing network pharmacology analysis and in vivo validation. PMC9709420, 2022.
17. Bukhari IA, et al. Piperine, an active ingredient of black pepper, attenuates acetaminophen-induced hepatotoxicity in mice. Res Gate archive.
18. Hassan HM, et al. The hepatoprotective effect of piperine against thioacetamide-induced liver fibrosis in mice: the involvement of miR-17 and TGF-β/Smads pathways. Front Pharmacol / PMC8585739, 2021.
19. Nagella P, et al. Therapeutic role of Cuminum cyminum on ethanol and thermally oxidized sunflower oil induced toxicity. Phytother Res. 2005;19(5):416–421.
20. Nagella P, et al. Role of Cuminum cyminum on ethanol and preheated sunflower oil induced lipid peroxidation. 2006.
21. Sultana S, et al. Comparative study of hepatoprotective effect produced by Cuminum cyminum, fruits of Phyllanthus emblica and silymarin against cisplatin-induced hepatotoxicity. Res Gate archive, 2017.
22. Talpate KA, et al. Supplementation of cumin seed powder prevents oxidative stress, hyperlipidemia and non-alcoholic fatty liver in high fat diet fed rats. Biomed Pharmacother. 2021.
23. Charaka Samhita, Chikitsa Sthana, Rasayana Adhyaya — description of Pippali Rasayana and Vardhamana Pippali Kalpa.